MINNEAPOLIS, Jan. 21 /PRNewswire-FirstCall/ -- ATS Medical, Inc. , manufacturer and marketer of state-of-the-art cardiac surgery products and services, today announced its participation in the 46th Annual Meeting of the Society of Thoracic Surgeons (STS) and related company-sponsored events. The meeting is scheduled from January 25-27, 2010, in Fort Lauderdale, Florida and serves as one of the year’s key gatherings of cardiovascular surgeons from around the world.
The Company is sponsoring a joint meeting with Intuitive Surgical entitled “Innovation Enables Progress: New Technologies Advancing Minimally Invasive and Robotic-Assisted Cardiac Surgery.” It will be held on Saturday, January 23rd at 6:30 pm (Eastern) at the Hilton Fort Lauderdale Marina. The program will focus on less invasive and robotic assisted cardiac procedures utilizing the ATS 3f(R) Aortic Bioprosthesis, the ATS Simulus(R) annuloplasty products and the ATS CryoMaze(R) Surgical Ablation System. Each of these products have unique features that facilitate their use in less invasive procedures.
The unique benefits of the ATS 3f(R) tissue valve products are generating enthusiasm and product demand among cardiac surgeons. The ATS 3f(R) Aortic Bioprosthesis is being implanted by growing numbers of surgeons and is the basis for the next generation ATS 3f(R) Enable Aortic Bioprosthesis. The Enable valve is the first surgical aortic valve replacement approved for commercial use that is implanted using a sutureless technique. It recently received CE Mark approval to distribute in the European Union. The Enable valve will be certain to generate excitement among the attendees at the STS meeting.
Hands-on demonstrations of all the unique technologies from ATS Medical will be available at the ATS Medical booth #1023.
ATS Medical, Inc. is dedicated to ‘Advancing The Standards’ of cardiac surgery through the development, manufacturing and marketing of innovative products and services for the treatment of structural heart disease. ATS Medical serves the cardiac surgery community by focusing on two distinct but operationally synergistic market segments: heart valve disease therapy and surgical ablation of cardiac arrhythmias.
Cautionary Statements
CONTACT: Michael Dale, President/CEO, +1-763-553-7736; or Michael Kramer,
CFO, +1-763-557-2222, both of ATS Medical, Inc.; or Investors, Parice
Halbert, CFA of Westwicke Partners, LLC, +1-443-213-0500, for ATS Medical,
Inc.
Web site: http://www.atsmedical.com/
